

Mylan

Multiple-Dose Vial

440 mg (trastuzumab) With Diluent

Ogivri™

LIFT TAB TO OPEN

Mylan

1 vial of trastuzumab / 1 vial of BWFI

Multiple-Dose Vial

440 mg (trastuzumab)

Ogivri™

Trastuzumab for injection (r-DNA origin) (Lyophilised powder)

For I.V. infusion, multiple-use vial

Bacteriostatic Water For Injection (BWFI):

Mfg Lic No: KTK/28/351/2005

Batch No.

Mfg Date:

Exp. Date:

BWFI not to be sold separately.

Trastuzumab:

Mfg Lic No: KTK/28D/7/2006

Batch No.

Mfg Date:

Exp. Date:

Trastuzumab for injection (r-DNA origin)

For I.V. infusion, multiple-use vial (Lyophilised powder)

Ogivri™ (trastuzumab)

440 mg

Mylan

Manufactured by: M/s. Biocon Limited Plot Nos. 2, 3, 4 & 5, Phase IV, Bommasandra-Jigani Link Road, Bommasandra Post, Bengaluru 560 099, India  
Manufactured for: Mylan Pharmaceuticals Private Limited, Plot No. 1-A/2, MIDC Industrial Estate, Rajga, Parvati, Dist. Raigad - 410205, Maharashtra, India  
Imported by: Meda Pharma (Thailand) Co., Ltd., (A Mylan company), Bangkok, Thailand



Trastuzumab for injection (r-DNA origin)

For I.V. Infusion, multiple-use vial (Lyophilised powder)

Ogivri™ (trastuzumab) 440 mg

Multiple-Dose Vial

1 vial of trastuzumab / 1 vial of BWFI

Mylan

Trastuzumab for injection (r-DNA origin)

For I.V. Infusion, multiple-use vial (Lyophilised powder)

Ogivri™ (trastuzumab) 440 mg

Composition:

Each combipack contains:

A. Trastuzumab for Injection. Each vial contains: Trastuzumab (r-DNA origin) 440 mg, L-Histidine Hydrochloride 9.9 mg, Polyethylene Glycol 3350 (Macrogol 3350) 98.6 mg, D-Sorbitol 337.9 mg  
B. Bacteriostatic Water for Injection USP (1 vial of 20 mL). Each mL contains: Benzyl Alcohol USP 1.1% v/v, Water for Injection USP q.s.

Storage: Store at temperature between 2°C to 8°C. Reconstitute with 20 mL Bacteriostatic Water for Injection USP (diluent) provided in this pack. Do not freeze the reconstituted solution. Use the solution within 28 days after reconstitution.

Keep out of reach of children.

Do not use in case any foreign particulate matter is observed inside the vial after reconstitution. Do not accept if vial seal is broken.

Dosage and Administration:

Read enclosed prescribing information sheet before use.

Reg No. 1C 15026/61 (NBS)

คำเตือนตามประกาศกระทรวงสาธารณสุข

ยานี้อาจทำให้เกิดคลื่นไส้อาเจียนได้ ต้องใช้ภายใต้การควบคุมของแพทย์เท่านั้น



Mylan